The REMS Filibuster: FDA Wants Ability To End Post-Approval Talks, Make Final Decision
Executive Summary
FDA wants a bigger stick for product-specific Risk Evaluation and Mitigation Strategy negotiations, if for no other reason than to end the talks and make the final decision.
You may also be interested in...
Burr Warns User Fee Renewal Could Be Difficult Without Performance Measure Improvements
Senator tells FDA Commissioner Hamburg that time to market is important metric during hearing dominated by questions about medical device review.
Cephalon’s Fentanyl Drugs Join Class-Wide REMS; Shared System Still To Come
Cephalon’s Actiq and Fentora will undergo increased distribution restrictions after joining FDA’s class-wide REMS for transmucosal fentanyl drugs, but a shared system, one of the main tenets of the risk management plan, is still under development.
Cephalon’s Fentanyl Drugs Join Class-Wide REMS; Shared System Still To Come
Cephalon’s Actiq and Fentora will undergo increased distribution restrictions after joining FDA’s class-wide REMS for transmucosal fentanyl drugs, but a shared system, one of the main tenets of the risk management plan, is still under development.